Astrazeneca Plc · LSE:AZN
Astrazeneca — Merger or Acquisition (December 2013)
10 slides from Astrazeneca's merger presentation, Dec 19, 2013
Slide 1: AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This presentation contains certain forward-looking statements
Slide 3: Diabetes is a large and growing health epidemic
Diabetes is a large and growing health epidemic Over …growing to over 550M by 2030 350M patients with …up to 50% of all cases are undiagnosed diabetes globally …2/3 of patients are living in emerging today markets Source: International Diabetes Federation 2011 – Regional estimates for diabetes (20-7
Slide 4: We are present in the fastest growing classes
We are present in the fastest growing classes Total market net sales, by class, $billions 2012-2018 CAGR +8% 60 52 DPP-4 10% 45 1 93%1 47% 38 SGLT-2 GLP-1 19% Insulin 5% Other² -3% 2012 2014 2016 2018 1. CAGR for SGLT-2s is 2014-2018 2. Includes SUs (sulphonylureas), TZDs (thiazolidinediones), metfo
Slide 5: Overview of existing Diabetes Alliance with Bristol-Myers Squibb
Overview of existing Diabetes Alliance with Bristol-Myers Squibb • Collaboration established in January 2007, included Onglyza and Forxiga franchises • Partnership to research, develop and commercialise novel drugs for Type 2 Diabetes • Partnership expanded in August 2012, through the acquisition of
Slide 6: Strategic drivers for acquiring the global rights to the Diabetes franchise
Strategic drivers for acquiring the global rights to the Diabetes franchise • Diabetes is a key growth platform for AstraZeneca • AstraZeneca has a core capability in primary care promotion and broad geographic presence in emerging and developed markets • Restructuring will give us more control whic
Slide 7: Financials
Financials • Transaction to be financed from existing cash resources and credit facilities • Initial payment $2.7bn • Up to $1.625bn in possible further payments (regulatory, launch & sales milestones; certain future assets) • Royalties on sales from 2014-2025 • Deal expected to close in January 201
Slide 8: Pro forma revenue 12M to 3Q 2013
Impact on AZ revenue of Transaction Pro forma revenue 12M to 3Q 2013 $bn $0.95bn
Slide 9: Activities to strengthen our diabetes portfolio
Activities to strengthen our diabetes portfolio Strengthening Simplify scientific leadership regimen Dual chamber pen EXSCEL Once-weekly/monthly CV outcomes study suspensions Label extensions1 DECLARE Dapa + CV outcomes study met Saxa + dapa FDC First DPP-4 CV outcomes Kombiglyze XR study Komboglyze
Slide 10: AstraZeneca to Acquire Bristol-Myers Squibb Share of Global Diabetes Alliance
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes Analyst call on19th December 2013